MAPT and Alzheimer disease: Moreover, tau‐PET imaging holds significant promise as a biomarker to improve differential diagnosis and expand pathophysiological insights in non‐AD tauopathies, including frontotemporal lobar degeneration (FTLD), which includes Pick's disease, progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD), with tracers like [18F]flortaucipir showing strong discriminatory power in differentiating AD and non‐AD diseases.24, 44